Skip to main content

Table 1 Basal characteristics of healthy and end-stage renal disease (ESRD) hemodialysis patients with targeted and with increased immunoreactive parathyroid hormone (iPTH)

From: The association of secondary hyperparathyroidism and myocardial damages in hemodialysis end-stage renal disease patients: assessed by cardiovascular magnetic resonance native T1 mapping

  Healthy subjects
(n = 30)
ESRD with targeted iPTH (n = 32) ESRD with increased iPTH(n = 40) P
Age (years) 48.1 ± 11.6 58.2 ± 13.9 57.4 ± 15.0 0.06
Gender (Male, n) 12(40.0%) 12(37.5%) 15(37.5%) 0.54
Height (cm) 152.8 ± 7.9 154.8 ± 23.1 156.5 ± 6.5 0.41
Weight (kg) 53.6 ± 6.6 50.3 ± 3.2 53.3 ± 9.6 0.47
Heart rate (beats/min) 71 ± 9 81 ± 12 78 ± 13 0.08
Duration of dialysis (M) N/A 12–132 9–228 0.06
Duration of renal insufficiency (M) N/A 12–156 12–228 0.06
Systolic BP N/A 136 ± 26 142 ± 20 0.34
Diastolic BP N/A 82 ± 13 89 ± 17 0.24
Causes of ESRD     
 Polycystic kidney disease (n, %) N/A 4(12.5%) 6(15.0%) N/A
  Primary glomerular nephropathy (n, %) N/A 23(44.3%) 29(55.8%) N/A
 Vasculitis (n, %) N/A 1(3.1%) 3(7.5%) N/A
 Genitourinary tuberculosis (n, %) N/A 2(6.3%) 4(10.0%) N/A
  1. Values are mean ± SD or n (%)
  2. M months, BP blood pressure, ESRD End-stage renal disease, CKD chronic kidney disease, iPTH immunoreactive parathyroid hormone